Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

GenScript debuts single- and double-strand DNA service for cell and gene therapy development

By Brian Buntz | May 16, 2022

GenScriptThe popularity of CRISPR-based non-viral gene insertion techniques is fueling interest in CRISPR/Cas genome-editing technology that uses the homology-directed repair (HDR) pathway to insert DNA sequences.

To respond to that demand, biotech services firm GenScript has introduced GMP-compliant single-stranded DNA (ssDNA) and closed-end linear double-stranded DNA (dsDNA) services.

The company’s GenExact ssDNA services support up to 5000 nt in length and 100mg per batch production scale.  GenWand services offer closed-end, linear dsDNA up to 10,000 nt in length and gram level/batch production scale.

Launching the services at the American Society of Gene & Cell Therapy annual meeting, Piscataway, New Jersey-based GenScript now boasts a range of non-viral HDR payload materials for early discovery research, process development and clinical trials.

The company said the offerings would also help facilitate CAR-T drug development.

“This new investment by GenScript demonstrates our commitment to non-viral delivery technology. We look forward to continuing to work with our partners and stakeholders in academia and industry to support their cell therapy R&D programs and further development of non-viral delivery platforms and workflows,” said Ray Chen, president of GenScript USA Life Science Group in a news release. “We know this technology will be a more efficient and safer solution for cell engineering.”

GenScript notes that researchers at the University of California, San Francisco (UCSF) have used its CRISPR RNP technology to knock out endogenous T-cell receptors and integrate replacement anti-cancer receptors.

GenScript researchers worked with UCSF researchers to engineer modifications to the DNA payload to promote co-localization and delivery to the nucleus.

The company’s GMP-compliant facilities are equipped with ISO Class 7 cleanrooms and ISO Class 5 isolators supporting aseptic processing.


Filed Under: Cell & gene therapy, Drug Discovery and Development
Tagged With: closed-end linear double-stranded DNA, CRISPR, dsDNA, GenScript, HDR, homology-directed repair, single-stranded DNA, ssDNA
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

How Thermo Fisher’s KingFisher PlasmidPro crunches hours of plasmid prep to 5 minutes hands-on
Can space help heal hearts? ISS study charts new path for stem cell therapy
MIT team designs gene circuits for tighter control in gene therapy study
Meet STITCHR, the retrotransposon-based gene editor that enables large, scarless DNA insertions
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE